je.st
news
Tag: ariad
Ariad Pharmaceuticals, Inc. (ARIA) Scheduled to Post Quarterly Earnings on Tuesday
2016-02-22 09:52:14| Biotech - Topix.net
Ariad Pharmaceuticals, Inc. will be releasing its Q415 earnings data on Tuesday, February 23rd. Analysts expect Ariad Pharmaceuticals to post earnings of per share and revenue of $44.79 million for the quarter.
Tags: post
tuesday
scheduled
quarterly
Premarket Biotech Digest: Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Guidance
2015-12-14 14:57:58| Biotech - Topix.net
I will be looking at some of the big names in the biotech sector over the next two weeks, starting with Gilead Sciences today. Within the large cap growth space in the biotech sector , Gilead continues to be my top pick.
Tags: deal
guidance
digest
biotech
Ariad shares fall as it cuts revenue guidance
2015-12-12 15:42:31| Biotech - Topix.net
Shares of Ariad Pharmaceuticals fell Friday after it cut revenue guidance as it continues to negotiate with French regulators over the price of its leukemia treatment, Iclusig. The Cambridge, Massachusetts-based developer of cancer treatments said that it previously expected to reach an agreement by the end of the year, but it now expects negotiations to continue into 2016.
Tags: fall
revenue
shares
guidance
Ariad Pharmaceuticals Sees Large Decline in Short Interest
2015-12-01 11:52:29| Biotech - Topix.net
Shares of Ariad Pharmaceuticals were the recipient of a significant decline in short interest in the month of November. As of November 13th, there was short interest totalling 30,675,599 shares, a decline of 4.3% from the October 30th total of 32,043,531 shares, AnalystRatings.Net reports.
Tags: large
short
interest
decline
a Ariad is at the bottom of a big biotech food chain, at least for now
2015-09-02 03:25:23| Biotech - Topix.net
The wave of merger-mania running through the biotech industry right now appears to be as much about companies trying not to be eaten as it is about companies eager to eat. That's according to Jacob Plieth , a reporter at EP Vantage with whom I interviewed last month regarding the attempt by Shire Pharmaceuticals to acquire newly launched Baxalta .